Logo SEFAC
Farm Comunitarios. 2022 Oct 21;14(4):38-41. doi: 10.33620/FC.2173-9218.(2022/Vol14).004.06

Dispensing Service: interaction between darunavir and quetiapine

Barris Blundell D1, Carrasco Naranjo O1
1. Farmacéuticos comunitarios en Farmacia Barris, Coín (Málaga)
Barris D, Carrasco O. Dispensing Service: interaction between darunavir and quetiapine. Farm Comunitarios. 2022 Oct 21;14(4):38-41. doi: 10.33620/FC.2173-9218.(2022/Vol14).004.06
Abstract : 

A 52-year-old male patient, with metabolic syndrome, Human Immunodeficiency Virus (HIV), insomnia, generalized anxiety disorder, schizophrenia and analgesic medication, who has been suffering from numerous nocturnal episodes of insomnia and restlessness. He had to be rescued by the emergency service when presenting a state of great confusion, agitation and a deep and marked tachycardia. The medication review allows us to associate these adverse events with an excess dose of quetiapine caused by the interaction with darunavir. The intervention consists of informing the doctor of the suspected influence of the interaction of darunavir with quetiapine and proposing the substitution of the antipsychotic for another that uses a different metabolic pathway. Darunavir is expected to increase the plasma concentrations of these antipsychotics, such as quetiapine (CYP3A inhibition). Co-administration of darunavir and quetiapine may be potentially serious as quetiapine-associated toxicity may be increased. The psychiatrist substitutes quetiapine for clotiapine. As of this change in medication, the patient no longer experiences any of the problems that afflicted him, in addition to the fact that he has regained sleep.

 
 
 
 
 

 

 
Keywords : 
Pharmacological interaction, darunavir, quetiapine, Community Pharmacy Services

Editor: © SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. 
Copyright© SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. This article is available from url https://www.farmaceuticoscomunitarios.org/. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

Share

-

Related contents

Published by

Manual for authors

Journal Information